Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-Guard for steroid-refractory acute graft-versus-host disease
NL-OMON44132Phase 2Active, not recruiting
- Sponsor
- Xenikos
- Start
- Mar 2014
- Modality
- Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of T-Guard in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Xenikos. Primary endpoint: Acute graft-versus-host disease response rate on Day 28. Started Mar 2014; status: active, not recruiting.
02
Drugs
T-Guard
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NL-OMON44132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44132.